Retrospective 64 COVID+ CAR-T cell therapy recipients, showing lower hospitalization with tixagevimab/cilgavimab prophylaxis in unadjusted results, without statistical significance.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, BQ.1.1 Planas, BA.5, BA.2.75, XBB Haars, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.1 Pochtovyi.
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
3.
Pochtovyi et al., In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1, Vaccines,
doi:10.3390/vaccines11101533.mdpi.com, doi.org.
|
risk of hospitalization, 19.0% lower, RR 0.81, p = 0.77, treatment 5 of 23 (21.7%), control 11 of 41 (26.8%), NNT 20.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Din et al., 8 Aug 2023, retrospective, USA, peer-reviewed, 24 authors, study period June 2020 - February 2022.
### P1540 COVID-19 INFECTION AMONG CAR-T CELL THERAPY RECIPIENTS: A SINGLE CENTER EXPERIENCE Topic: 30. Infections in hematology (incl. supportive care/therapy)
Mohammad Ammad, Ud Din, Nayeon Oh, Aliyah Baluch, Olga Klinkova, Rod Quilitz, Melissa Alsina, Nelli Bejanyan, Omar Castaneda, Julio Chavez, Hany Elmariah, Ciara Freeman, Doris Hansen, Michael Jain, Farhad Khimani, Aleksandr Lazaryan, Hien Liu, Asmita Mishra, Leonel Ochoa, Lia Perez, Joseph Pidala, Bijal Shah, Taiga Nishihori, Frederick Locke, Rawan Faramand
Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
